- MGI Pharma has acquired the worldwide rights to two late-stage development products from ILEX Oncology of the USA. The products in question are DHAC (dihydro-5-azacytidine) and oxypurinol. DHAC has the potential to treat several different tumor types, eg prostate cancer, as well genetic blood diseases including myelodysplastic syndrome and thalassemia major, says the company. A Phase II study with the drug will begin in 1997 to treat MDS, a bone marrow disease. Oxypurinol is a second-line ther-apy for gout. MGI intends to submit a New Drug Application for oxypurinol with the US authorities in 1997.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze